Maxygen

What is Maxygen?

Maxygen is a biopharmaceutical company that specializes in protein drug improvement using innovative technology.

They deploy their proprietary MolecularBreeding directed evolution technology platform and a combination of ancillary technologies to create superior versions of protein drugs, also known as biosuperior proteins. Their expertise in protein modification is aimed at advancing the healthcare industry by enhancing the efficacy, safety, and overall value of therapeutic proteins. In addition to internal development, Maxygen actively engages in external collaborations and other arrangements to expand its reach and impact within the biotech sector.

Maxygen's approach to synthetic biology and natural diversity includes developing libraries of genetic diversity that are high in functional content. Their EvoGenerative computational methods enable scalable library design, offering a cost-effective solution for directed evolution screening campaigns.

A key aspect of their business model is the non-retention of ownership in the projects they collaborate on; partners retain the ownership of the materials and results derived from these collaborations. Maxygen offers molecular biology services such as DNA synthesis, mutational, assembly, and cloning technologies to facilitate molecular biology workflows.

This allows their partners to save time and explore a broader landscape of biotechnological opportunities.

In certain areas of biotech, Maxygen also performs screening of libraries to assist project development. The company is recognized as a leader in applying synthetic biology to directed evolution for protein engineering, helping to enhance protein function across various areas of biotechnology.